| INTRODUC TI ON
Tumor dormancy is classically defined as the arrest of tumor growth in the primary site or in metastatic dissemination. The concept of dormancy is derived from clinical findings that cancer recurs several years or even decades after surgical resection of the primary tumor, especially in breast and prostate cancers. 1, 2 In tumor mass dormancy, there is a balance between the increase in cancer cells by proliferation and the decrease by cell death; whereas, in cellular dormancy, cancer cells are in a quiescent state ( Figure 1 ). Here, we introduce the clinical relevancy and the mechanisms underlying tumor dormancy.
| CLINIC AL IN S I G HTS
Breast cancers are divided into several subgroups based on receptor expression and proliferation activity. Relapse-free survival times differ among the subtypes. In the human epidermal growth factor receptor 2 (HER2)-positive or triple-negative subtypes, which have high proliferation activity, the latent periods are shorter than for other subtypes. In these aggressive tumors, the frequency of late recurrence after 5 years is rather reduced 3, 4 compared with other subtypes that may recur even after 20 years. 5, 6 Estrogen receptor (ER)-positive breast cancer is a clinical model of late recurrence. A clinical study was carried out evaluating adjuvant therapy with tamoxifen against ER-positive breast cancer. 7 Continuing tamoxifen for 10 years rather than stopping at 5 years further reduced recurrence and mortality, particularly after 10 years. These results indicate that ER-positive cancer cells could be dormant and survive for more than 5 years; thus, prolonged treatment is required. Recurrences after long-term latency are also reported in other cancers, such as melanoma and renal cell carcinoma. 8, 9 In prostate cancer, there are some cases in which serum levels of prostate specific antigen (PSA) increase without apparent recurrence of the tumor after primary therapy; this is called "PSA recurrence". The actual recurrences occur an average of 8 years after PSA recurrence. 
| TUMOR MA SS DORMAN C Y
To explain late recurrence, a model of "tumor mass dormancy" was proposed that assumed the balance between the increase in cancer cells by proliferation and the decrease by cell death was at equilibrium. Tumor mass dormancy can be achieved by two different mechanisms; angiogenic dormancy and immunomediated dormancy.
| Angiogenic dormancy
To support active proliferation, cancer cells consume large amounts of energy resources. To meet this necessity, tumor growth must be accompanied by the generation of a new network of blood vessels or angiogenesis. 12 Angiogenesis is finely regulated by pro-angiogenic factors and anti-angiogenic factors. 13 After the angiogenic switch, when the balance tilts to the pro-angiogenic side, a tumor enters into the progression phase. 14 
| Immunomediated dormancy
Immune-surveillance has long been known as a critical factor for suppression of tumor development and growth, and tumor cells in established tumors acquire the ability of immune-evasion. 18, 19 The immune system plays critical roles not only in avoiding the early establishment of tumors, [20] [21] [22] but also in tumor mass dormancy. 
| CELLUL AR DORMAN C Y
Cellular dormancy is another model of tumor dormancy. 
| Extracellular matrix and dormancy
The microenvironment of the metastatic site in a distant organ should not be the same as that of the original tumor, and in such an aberrant milieu, cancer cells die or become dormant. The extracellular matrix is an important microenvironmental factor. Aguirre-Ghiso et al 29 reported that the ratio of active ERK and p38MAPK by attachment to the extracellular matrix is the molecular switch for cellular dormancy. 
| Hypoxic microenvironment and dormancy
Disordered proliferation of cancer cells and disorganized angiogenesis make the cancer microenvironment hypoxic. Consumption of oxygen by tumor cells plays a critical role in generating a hypoxic microenvironment. 40 Hypoxia induces a malignant phenotype and therapy resistance in cancer. 41 We reported that vascular endothelial growth factor (Vegf ) is necessary for angiogenesis and the formation of pancreatic islet cell tumors in transgenic RIP1-Tag2 mice, 42 whereas tumors still exist in the Vegf null RIP1-Tag2 mice in an hypoxia-inducible factor (HIF)1α-dependent way. 43 The residual tumors are highly hypoxic with decreased proliferation and cell death. Both genetic and pharmacological inhibition of angiogenesis result in the tumors having an invasive phenotype. 44 Using cell tracking experiments, Harada et al 45 showed that the hypoxic cells are the origin of recurrence after irradiation in vivo.
The transcription factor HIF plays a central role in acute hypoxic response in cancer cells. 46 Acute hypoxic responses have been intensively studied, using established cell lines fully supplied with nutrients except for oxygen for a short period, from several hours to 48 hours.
Under such acute hypoxic conditions, glucose consumption drastically increases because of activated glycolysis (Figure 4) . Under a microenvironment in which the glucose supply is limited, it is not likely that cancer cells will continue to consume large amounts of glucose.
Thus, there should be other mechanisms different from the typical acute hypoxic response for the dormant cancer cells in hypoxia.
A pancreatic cancer cell line, AsPC-1, was dormant in chronic hypoxia during in vitro experiments. 40 The consumption of energy resources, such as oxygen and glucose, and ATP turnover are decreased in the dormant state. In contrast to the acute hypoxic response, the production of lactate, an end-product of glycolysis, promoter is methylated, the gene is not induced in hypoxia alone.
Under glucose-deprived conditions, DNA methyltransferase activity is suppressed, the HIGD1A promoter is demethylated, and HIGD1A is induced. HIGD1A suppresses oxidative phosphorylation, activates AMPK, and suppresses reactive oxygen species (ROS) production. Consequently, HIGD1A supports the survival of cancer cells under severely hypoxic conditions. 47 The orphan nuclear receptor, NR2F1, plays a role in the maintenance of dormancy through SOX9, PARβ, and CDK inhibitors in HEp3 cells.
48
Using patient-derived xenograft models, Fluegen et al 49 reported
that an increase of p27 through NR2F1 and HIF1α is necessary for induction of dormancy in disseminated tumor cells using patientderived xenograft models.
| Experimental platform for studying cellular dormancy of cancer in vitro
Establishing a model system has long been a critical concern for studying tumor dormancy in vitro. Recently, we developed a novel primary culture system of cancer cells, the cancer tissue-originated spheroid (CTOS) method. The principle of the CTOS method is to maintain cell-cell contact throughout the preparation and culture processes. CTOS retains the characteristics of the original patients'
tumors. 50 In addition, CTOS can be reversibly dormant for at least 7 days in hypoxia without growth factor stimulation for colorectal cancer. 40, 51 All of the examined CTOS derived from different patients can be dormant, suggesting that cellular dormancy is a common feature of cancer cells and is not restricted to particular cell lines.
| Suppression of the oncogenic pathway
The oncogene MYC is one of the most frequently dysregulated genes in many cancers. 52 In mice with liver tissue-specific tet-off MYC gene expression, MYC is overexpressed in the absence of doxorubicin (Dox) treatment, and tumors are generated in the liver. MYC activation stimulates both oxygen and glucose consumption. 54 We showed that MYC protein levels drastically decreased under glucose-and oxygen-deprived conditions through enhancement of protein degradation. Cell death of colorectal cancer HCT116 cells is alleviated by suppression of MYC under prolonged glucoseand oxygen-deprived conditions. MYC levels are frequently increased in colorectal cancer 55 and decreased in hypoxia in CTOS (M.
Inoue, unpubl. data). Regulation of MYC levels might also be involved in the induction of dormancy.
A driver mutation is a mutation within a gene that plays a critical role in cancer development and progression. 
| Endoplasmic reticulum stress and dormancy
As mentioned above, some cells can be dormant only under some conditions. To be dormant, there should be a particular cellular context or cue, such as a hypoxic response. Another signal may be endoplasmic reticulum (ER) stress. In actively dividing cancer cells, protein synthesis that requires large amounts of energy resources is promoted. Protein synthesis and the key molecule, mTORC1, are downregulated in cancer cells cultured in hypoxia. 59 When a colorectal cancer cell line, COLO320, was stimulated by insulin-like growth factor (IGF) under hypoxic conditions, robust apoptosis was induced through an augmented ER stress response. 60 Impaired protein folding under hypoxic conditions is responsible for the ER stress, and IGF might induce ER stress by stimulating aberrant protein synthesis and consequent cell death. Thus, too much ER stress must be avoided.
Ranganathan et al 61 reported that activation of p38 MAPK through ER stress is critical for induction of dormancy.
| FINAL REMARK S
Although the phenomenon of dormancy is becoming increasingly recognized in the field of cancer research, the mechanisms for it are still largely unknown. One of the reasons is that "dormancy" includes many different states that depend on cell type; nutrient levels, oxy- 
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